nderstanding the impact of proactive management to improve symptomatic contact lens wearers success

CooperVision (United States)0 个研究点目标入组 81 人开始时间: 2021年1月28日最近更新: 2021年8月2日

试验速览

暂无简介。

•1. Age 18 to 40 years
•2. Current daily wear soft contact lens wearer who have worn contact lenses for at least six months in total
•3. CLDEQ-8 =14 and/or comfortable wearing time = 9hrs; with selfreported end of day dryness or discomfort
•4. Spectacle refraction:
•Sphere: -6.00D to + 4.00D
•Astigmatism: 0.00D to -0.75
•5. Best corrected visual acuity of at least 20/30 in each eye
•6. No significant ocular signs that would prohibit contact lens wear including:
•6.1. Blepharitis score <3 (0 to 4-point scale)
•6.2. Meibomian gland score <3 (0 to 4-point scale)
•6.3. Corneal staining score <7 (0 to 10-point scale)
•6.4. Conjunctival staining score <3 on (0 to 4-point scale)
•6.5. TPH without contact lenses =0.125 mm
•6.6. OSDI score without contact lenses <13
•7. Have read and understood the Participant Information Sheet in English
•8. Have read, signed and dated the Informed Consent
•9. Have normal eyes with the exception of the need for visual correction
•10. Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule

•1. Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear
•2. Monocular participants (only one eye with functional vision) or participants fit with only one lens
•3. Any moderate or severe ocular condition observed during the slit-lamp examination at the enrolment visit
•4. History of herpetic keratitis, ocular surgery or irregular cornea
•5. Known pregnancy or lactation during the study period as determined by self-report
•6. Enrolment of the investigator or his/her staff, family members of the investigator, family members of the investigator’s staff, or individuals living in the households of these individuals
•7. Individuals who are unable to read or understand the Participant Information Sheet in English

发起方

CooperVision (United States)